secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2023-01-12T23:59:59+00:00
Accession:  0000950103-23-000404
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen reports pipeline progress and R&D Day for PRGN-2012 data on Jan 24, 2023
--------------------------------------------------------------------------------

- PRGN-2012 Phase 2 enrollment rapid; 20 patients enrolled; R&D Day Jan 24 to share Phase 1 data.
- PRGN-2009 Phase 2 monotherapy arm near full enrollment: 19 of 20 patients; interim data expected H2 2023.
- PRGN-3006 in AML: Phase 1 dose escalation data presented at ASH; Phase 1b expansion includes Mayo Clinic; first repeat dose cleared.
- PRGN-3005 in ovarian cancer: Phase 1 dose escalation completed; first repeat dose given; expansion enrollment ongoing.
- PRGN-3007 (next-gen UltraCAR-T) trial open for enrollment; first patient dosing expected Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010323000404/0000950103-23-000404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010323000404/dp186955_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-23-000404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer